The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

A phase 1/2 open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of BH-30643 in adult subjects with locally advanced or metastatic NSCLC harboring EGFR and/or HER2 mutations (SOLARA).

Xiuning  Le

Consulting or Advisory Role - Abbvie; ABION; Allyst; ArriVent Biopharma; ArriVent Biopharma; AstraZeneca; Aviston; Bayer; Black Diamond Therapeutics; BlossomHill Therapeutics; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo/Lilly; EMD Serono; Hengrui Therapeutics; Janssen Oncology; Lilly; Merus; Novartis; PineTree; Regeneron; Spectrum Pharmaceuticals; Systimmune; Taiho Pharmaceutical

Research Funding - ArriVent Biopharma (Inst); Boehringer Ingelheim (Inst); EMD Serono (Inst); Janssen (Inst); Lilly (Inst); Regeneron (Inst); Teligene (Inst)

Travel, Accommodations, Expenses - EMD Serono; Johnson & Johnson/Janssen; Regeneron; Spectrum Pharmaceuticals

Alexander  Spira

Leadership - Next Oncology (Inst)

Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda

Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda

Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)

Melissa  Johnson

Consulting or Advisory Role - Abbvie (Inst); Alentis Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); Biohaven Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Hookipa Biotech (Inst); Immunocore (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); ModeX Therapeutics (Inst); Normunity (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sanofi (Inst); SeaGen (Inst); Synthekine (Inst); Takeda (Inst); Zai Lab (Inst)

Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); ArriVent Biopharma (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); City of Hope (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); EQRx (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immuneering (Inst); Immunitas (Inst); Immunocore (Inst); IMPAC Medical Systems (Inst); Incyte (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Lilly (Inst); LockBody Therapeutics (Inst); Loxo (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); Mythic Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Nextpoint (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoC4 (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scorpion Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Summit Therapeutics (Inst); Syndax (Inst); Systimmune (Inst); Taiho Oncology (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); TheRas (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); Vividion Therapeutics (Inst); Vyriad (Inst); Y-mAbs Therapeutics (Inst)

Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi

Misako  Nagasaka

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb USA; Caris Life Sciences; Daiichi Sankyo; EMD Serono; Genentech; Janssen; Lilly; Mirati Therapeutics; Novartis; Pfizer; Regeneron; Takeda

Speakers' Bureau - Blueprint Medicines; Janssen; Mirati Therapeutics; Mirati Therapeutics; Takeda

Research Funding - Tempus

Travel, Accommodations, Expenses - Anheart Therapeutics

Alexander  Philipovskiy

Research Funding - Abbvie (Inst); Abbvie (Inst); Accutar Biotech (Inst); Agenus (Inst); Arvinas (Inst); Astellas Pharma (Inst); BeiGene (Inst); Frontier Med (Inst); GlaxoSmithKline (Inst); Immuneering (Inst); Inspirna (Inst); Janssen Research & Development (Inst); KAHR Medical (Inst); Loxo/Lilly (Inst); Monte Rosa Therapeutics (Inst); Valerio (Inst)

Jyoti  Patel

Consulting or Advisory Role - Abbvie; Anheart Therapeutics; AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Astra Zeneca; Genentech; Gilead Sciences; Guardant Health; Sanofi; Takeda Science Foundation

Travel, Accommodations, Expenses - Tempus

Sarah  Gordon

Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/UCB Japan

Jonathan  Riess

Consulting or Advisory Role - Amgen; Bicycle Therapeutics; Bristol-Myers Squibb/Celgene; Catalyst Clinical Research; Daiichi Sankyo; Genentech; GlaxoSmithKline; Janssen Oncology; Merck; Merus NV; Oncohost; Pfizer; Regeneron; Replimune

Research Funding - ArriVent Biopharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); IO Biotech (Inst); Kinnate Biopharma (Inst); Merck (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); Pfizer; Revolution Medicines (Inst); Summit pharmaceuticals (Inst)

Travel, Accommodations, Expenses - AstraZeneca; IO Biotech

Lyudmila  Bazhenova

Consulting or Advisory Role - Abbvie; Anheart Therapeutics; AstraZeneca; Bayer; BioAtla; BMS GmbH & Co. KG; Boehringer Ingelheim; daichi; Genentech/Roche; Gilead Sciences; Janssen Oncology; Merck; Natera; neuvogen; Novocure; Pfizer; Regeneron; Sanofi; Summit pharmaceuticals; Teligene

Sonam  Puri

Honoraria - Aptitude Health (Inst); IntegrityCE

Consulting or Advisory Role - Abbvie (I); Bristol Myers Squibb Foundation; Bristol-Myers Squibb/Roche; G1 Therapeutics; Intuitive Surgical (I); Janssen; Jazz Pharmaceuticals (Inst); Novocure; Oncohost; Pfizer; Takeda

Travel, Accommodations, Expenses - Dava Oncology; Henlius

Hidehito  Horinouchi

Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical

Consulting or Advisory Role - Abbvie; AstraZeneca; BlossomHill Therapeutics, Inc.; Chugai Pharma; Daiichi Sankyo; Genmab; Novocure; Seagen; Yuhan

Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BlossomHill Therapeutics, Inc. (Inst); BMKK (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Genmab (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)

Hiroki  Izumi

Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo/UCB Japan; Lilly; Merck; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda

Consulting or Advisory Role - Amgen

Research Funding - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Eisai/MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)

Molly  Li

Honoraria - ACE oncology; Amgen; Anheart Therapeutics; AstraZeneca; Gilead Sciences; Janssen; Merck KGaA; MSD; Novartis; Pfizer; Takeda; Zai Lab

Consulting or Advisory Role - Amgen; Anheart Therapeutics; AstraZeneca; Johnson & Johnson/Janssen; Pfizer; Takeda; Yuhan; Zai Lab

Research Funding - AstraZeneca; Gilead Sciences; MSD Oncology

Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo/UCB Japan; Pfizer; Roche; Zai Lab

Tom  John

Honoraria - AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech

Consulting or Advisory Role - Amgen (Inst); AstraZeneca; AstraZeneca/MedImmune; Bayer (Inst); Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca (Inst); Gilead Sciences; Ignyta; Johnson & Johnson/Janssen (Inst); Medison (Inst); Merck KGaA; MSD Oncology; Novartis; Pfizer; PharmaMar (Inst); Roche/Genentech; Seagen (Inst); Specialised Therapeutics

Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche; Roche

Sagun  Parakh

Honoraria - MSD Oncology; Roche

Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Australia Pty Ltd

Armin  Graber

Employment - BLOSSOMHILL THERAPEUTICS

Stock and Other Ownership Interests  - BLOSSOMHILL THERAPEUTICS

Geoff  Oxnard

Employment - Foundation Medicine; LOXO at Lilly

Stock and Other Ownership Interests  - Lilly; Roche

J. Jean  Cui

Employment - BlossomHill Therapeutics; BlossomHill Therapeutics (I)

Leadership - BlossomHill Therapeutics; BlossomHill Therapuetics (I)

Stock and Other Ownership Interests  - BlossomHill Therapeutics; BlossomHill Therapeutics (I)

Patents, Royalties, Other Intellectual Property - BlossomHill Therapeutics; BlossomHill Therapeutics (I)

Pingkuan  Zhang

Employment - BlossomHill Therapeutics; Takeda

Leadership - BlossomHill Therapeutics

Stock and Other Ownership Interests  - GlaxoSmithKline; Johnson & Johnson; Novartis; Pfizer; Takeda

James ChihHsin  Yang

Honoraria - Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo/Astra Zeneca (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)

Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Takeda (Inst)

Research Funding - AstraZeneca (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Dizal Pharma; Takeda